Commercial OpportunityConsidering the ongoing stimulant shortages and that CTx-1301 only requires one dose daily, the commercial opportunity for Cingulate is attractive.
Drug Delivery TechnologyCingulate's Precision Timed Release (PTR) drug delivery technology can deliver once-daily oral therapies that provide all-day efficacy while eliminating the need for boosters.
Regulatory Approval ProcessThe FDA suggested that Cingulate may file an NDA for CTx-1301 with existing data, indicating that sufficient data is already available for submission.